ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announces that research investigators and scientists will present data from 32 accepted scientific abstracts or short articles at the International Neuromodulation Society (INS) 12th World Congress June 6-11 in Montreal, Canada. Throughout the congress, oral and poster presentations will highlight extensive research advancing St. Jude Medical’s product portfolio for the treatment of chronic pain, including presentations related to radiofrequency ablation (RFA), and spinal cord stimulation (SCS) including a focus on both Burst stimulation and stimulation of the dorsal root ganglion (DRG).
INS attendees will also have the opportunity to view St. Jude Medical’s latest technologies in the company’s Innovation Suite and at the St. Jude Medical booth (# 22). Highlighted products will include the Protégé MRI™ and Prodigy MRI™* chronic pain systems, the Axium™ Neurostimulator System* for DRG stimulation, St. Jude Medical’s RFA products, and other innovative technology.
St. Jude Medical’s DRG stimulation will be the focus of many presentations during INS 2015, which will examine the therapy’s ability to offer physicians more options to effectively manage their patients’s chronic pain. Stimulation of the DRG with the Axium™ Neurostimulator System* has been shown to provide meaningful relief for patients battling chronic pain, and is especially useful for treating focal pain areas often challenging to treat using traditional SCS.
On June 8, 2015, Timothy Deer, M.D., and Robert Levy, M.D., Ph.D., will present results from the ACCURATE Study, a multi-center, randomized controlled pivotal clinical trial designed to evaluate the safety and efficacy of the Axium™ Neurostimulator System*. The ACCURATE Study, which enrolled 152 patients at 22 centers throughout the U.S., represents the largest neuromodulation study to date assessing patients suffering from nerve injuries (peripheral causalgia) or complex regional pain syndrome (CRPS).
Additional sessions during INS 2015 will examine DRG stimulation’s impact on pain relief, mood, and quality of life in patients suffering a broad range of conditions, including chronic post-surgical pain and focal neuropathic pain, and in patients who have failed traditional and high frequency spinal cord stimulation. Researchers will also present a sub-analysis from the EMPOWER registry and assessments of the safety and efficacy of the St. Jude Medical Penta™ 5-Column paddle lead. Other abstracts include a subanalysis on the Burst pre-market study which evaluated the differences in device use for patients receiving tonic stimulation versus burst stimulation, and an animal study that helps to further differentiate the mechanism of action of burst stimulation versus traditional tonic stimulation. Finally, results from the EVEREST trial, which evaluated the long-term safety and efficacy of cortical stimulation for stroke rehabilitation patients will also be presented.
For a full list of St. Jude Medical research abstracts scheduled to be presented at INS 2015, visit sjm.com/INS.
*Caution: Device not approved in the U.S., and is limited by Federal (or United States) Law to investigational use.
About the St. Jude Medical Chronic Pain Portfolio
Chronic pain affects approximately 1.5 billion people worldwide, more than heart disease, cancer and diabetes combined. The condition can negatively impact personal relationships, work productivity and a patient’s daily routine. St. Jude Medical offers multiple solutions for patients to manage debilitating chronic pain, including spinal cord stimulation (SCS), spinal cord stimulation targeting the DRG, and radiofrequency ablation.
About St. Jude Medical
St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2015 and Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2015. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.